Additional file 2 of Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma
- Visconti, Alessia
- Rossi, Niccolò
- Deriš, Helena
- Lee, Karla A
- Hanić, Maja
- Trbojević-Akmačić, Irena
- Thomas, Andrew M.
- Bolte, Laura A.
- Björk, Johannes R.
- Hooiveld-Noeken, Jahlisa S.
- Board, Ruth
- Harland, Mark
- Newton-Bishop, Julia
- Harries, Mark
- Sacco, Joseph J.
- Lorigan, Paul
- Shaw, Heather M.
- de Vries, Elisabeth G.E.
- Fehrmann, Rudolf S.N.
- Weersma, Rinse K.
- Spector, Tim D.
- Nathan, Paul
- Hospers, Geke A. P.
- Sasieni, Peter
- Bataille, Veronique
- Lauc, Gordan
- Falchi, Mario
- Faculteit Medische Wetenschappen/UMCG
- Damage and Repair in Cancer Development and Cancer Treatment (DARE)
- Guided Treatment in Optimal Selected Cancer Patients (GUTS)
- Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI)
- King's College London
- Genos Glycoscience Research Laboratory
- University of Trento
- University Medical Center Groningen
- University of Groningen
- Arctic Centre, Univ. of Groningen
- Lancashire Teaching Hospitals NHS Foundation Trust
- University of Leeds
- Evelina London Children's Hospital
- University of Liverpool
- The Clatterbridge Cancer Centre NHS Foundation Trust
- The Christie NHS Foundation Trust
- East and North Hertfordshire NHS Trust
- West Herts NHS Trust
- University of Zagreb
DOIAbstract
Additional file 2: Table 1. Description of total serum N-glycan UHPLC measured peaks. Table 2. Description of total serum derived traits. Table 3. Summary statistics for the associations between N-glycan traits and response to ICI treatment. Table 4. Summary statistics for the associations between N-glycan traits and progression-free survival. Table 5. Summary statistics for the associations between N-glycan traits and overall survival. Table 6. Summary statistics for the N-glycans shift at follow up with respect to the pre-treatment relative abundances
Add to ORKG